Teva's Big Bet on Neuroscience: A Recipe for Success or Disaster?
Teva Pharmaceutical Industries Limited has agreed to serve as the stalking horse bidder for BioXcel Therapeutics' assets in a deal valued at up to $125 million.
The agreement includes two neuroscience focused assets, Igalmi and BXCL501, which have the potential to disrupt traditional treatment models.